Implementation of Whole-Body MRI (MY-RADS) within the OPTIMUM/MUKnine multi-centre clinical trial for patients with myeloma
Mihaela Rata(Royal Marsden Hospital), Christina Messiou(Institute of Cancer Research), Erica Scurr(Royal Marsden NHS Foundation Trust), Matthew Blackledge(Institute of Cancer Research), Antonio Candito(Institute of Cancer Research), Arnold Drury(Royal Bournemouth and Christchurch Hospitals NHS Foundation Trust), Dow‐Mu Koh(Royal Marsden NHS Foundation Trust), Winston J. Rennie(Leicester Royal Infirmary), Alina Dragan(Royal Marsden NHS Foundation Trust), Mauro Albrizio(Nottingham University Hospitals NHS Trust), Suchi Gaba(Royal Stoke University Hospital), Anjumara Nilak(Worcestershire Acute Hospitals NHS Trust), Paul Malcolm(Norfolk and Norwich University Hospital), Sarah Brown(University of Leeds), Martin Kaiser(Royal Marsden NHS Foundation Trust), Sadie Roberts(University of Leeds), Matthew Jenner(University Hospital Southampton NHS Foundation Trust), Alexander King(University Hospital Southampton NHS Foundation Trust), Sanjay Gandhi(Teva Pharmaceuticals (United States)), Amy Davis(Epsom and St Helier University Hospitals NHS Trust), Jessica Winfield(University Hospitals Birmingham NHS Foundation Trust), Priya Suresh(University Hospitals Plymouth NHS Trust), Aarti Abhishek Shah(Manipal Academy of Higher Education)
Cited by 23
Related Papers
Patient-derived organoids model treatment response of metastatic gastrointestinal cancers
|Science|2018|2.1k
Comparative effectiveness of MRI in breast cancer (COMICE) trial: a randomised controlled trial
|The Lancet|2010|640
Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma
|Journal of Clinical Oncology|2015|564